NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
- Conditions
- AIDS-Related-Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00267865
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT00265798
- Locations
- πΊπΈ
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
πΊπΈUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
πΊπΈDecatur Memorial Hospital, Decatur, Illinois, United States
Weight Management in Nonalcoholic Steatohepatitis
- Conditions
- Fatty Liver
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2010-01-13
- Target Recruit Count
- 30
- Registration Number
- NCT00266019
- Locations
- πΊπΈ
Rhode Island Hospital, Providence, Rhode Island, United States
Frequent Hemodialysis Network: Daily Trial
- Conditions
- End Stage Renal Disease
- Interventions
- Device: Conventional hemodialysisDevice: Frequent hemodialysis
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2014-07-03
- Target Recruit Count
- 245
- Registration Number
- NCT00264758
- Locations
- πΊπΈ
University of California at San Francisco - Core center plus other centers in California and Texas, San Francisco, California, United States
πΊπΈRenal Research Institute - Core center plus other centers in U.S. and Canada, New York, New York, United States
A Self-care Intervention for Latino Adults With Diabetes
- Conditions
- HypertensionDiabetes
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 300
- Registration Number
- NCT00263835
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
- Conditions
- Stage II Breast CancerStage III Breast CancerBreast CancerStage I Breast Cancer
- Interventions
- Other: conventional surgery
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00262834
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous Adenocarcinoma
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker AnalysisOther: PlaceboOther: Quality-of-Life Assessment
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1873
- Registration Number
- NCT00262847
- Locations
- πΊπΈ
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
πΊπΈMemorial Hospital at Easton - Shore Regional Cancer Center, Easton, Maryland, United States
πΊπΈCleveland Clinic Foundation, Cleveland, Ohio, United States
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
- Conditions
- Cervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Squamous Cell CarcinomaStage IB Cervical CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage IVA Cervical Cancer
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 402
- Registration Number
- NCT00262821
- Locations
- πΊπΈ
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
πΊπΈArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
πΊπΈThomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00262925
- Locations
- πΊπΈ
Mercy Hospital and Medical Center, Chicago, Illinois, United States
πΊπΈCase Western Reserve University, Cleveland, Ohio, United States
πΊπΈRush - Copley Medical Center, Aurora, Illinois, United States
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
- Conditions
- Chronic Sleep DeprivationObesity
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2015-11-04
- Target Recruit Count
- 239
- Registration Number
- NCT00261898
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States